Mission Future Diagnostics intends to become the best developer for third parties of high‐quality and innovative diagnostic tests, today, and in the future, seen in the eyes of our customers and our employees.
Vision Future Diagnostics intends to become the market leader in test development for third parties We want to become the independent partner of the top 25 IVD companies for their test development We would like to achieve this position by translating new technologies and novel ‘Intellectual Properties’ to the development of innovative tests with the shortest possible development time at the lowest possible costs
Facts Founded May 01st, 1997 Privately owned Current number of employees is 65 Current number of projects is 35 out of a maximum of 40 Highly qualified staff ISO 9001/2000 and ISO 13485 compliant FDA inspections in 2004 and 2008
Objective The development of diagnostic tests and technologies for third parties We are able to carry out development projects on almost any platform Antibody Screening Feasibility Optimization Verification Technical Validation Clinical Validation Pilot Production Support in 510(k) filing and CE registration
Facilities Total 3500 m2 ( Lab: 2000 m2 ) Operational February 2011
> 120 developed assays Bone Fertility CancerBioactive PTH Aldosterone β‐2MCalcitonin Androstendione EGFCip and Cap 11‐Desoxy‐cortisol EGF receptorDPD DHEA E2 receptorIntact‐PTH DHEA‐S Free PSAPTH DHT IGF‐1PTHrp Estradiol IGFBP31,25‐OH Vitamin D Estriol P5325‐OH Vitamin D Free testosterone Progesterone receptorVitamin D BP hCG PSA LH 17‐OH Progesterone SHBG Testosterone
LiquiditeitHoe blijf ik aan mijn kortlopende verplichtingen voldoen?
Trends in healthcare• Less than 5% of the $3 trillion spent each year on the health care worldwide is for clinical laboratory services.• Considering that nearly 70% of health care decisions are based on critical diagnostics information, biomedical testing represents a significant source of value in healthcare. Source: TriMark Publications